Frédéric Schmidt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Frédéric Schmidt has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Jean-Claude Florent
CNRS UMR 176, 26 rue d’Ulm, 75248 Paris, France
10 shared publications - Ludovic Jullien
PSL University, Sorbonne Université, CNRS
9 shared publications Thomas Le Saux
PASTEUR, Département de chimie, École normale supérieure, PSL University, Sorbonne Université, CNRS, 24, rue Lhomond, 75005 Paris, France
9 shared publicationsAhmed Alouane
Institut Curie
8 shared publicationsClaude Monneret
UMR 176 CNRS/Institut Curie, Centre de Recherche, 26 rue d'Ulm, 75248 Paris Cedex 05, France
8 shared publications- Ludger Johannes
Chemical Biology of Cancer Unit, Institut Curie, U1339 INSERM, UMR3666 CNRS, PSL Research University, Paris, France
7 shared publications
Latest Publications
- 5 September 2023
- Published by Elsevier in Biomaterials
- Vol. 302, 122298
A synthetic delivery vector for mucosal vaccination
- 5 September 2023
- Published by Elsevier in Biomaterials
- Vol. 302, 122298
A synthetic delivery vector for mucosal vaccination
- 1 December 2021
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 20 (1) , 240-246
A double-triggered self-immolative spacer for increased selectivity of molecular release
A self-immolative spacer based on dissymmetrical N,N′-bis-carbamate aniline is introduced to liberate a substrate from a precursor after dual activation. The proof of principle of its exclusive selectivity for substrate liberation has been conducted on a profluorophore.
- 1 December 2021
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 20 (1) , 240-246
A double-triggered self-immolative spacer for increased selectivity of molecular release
A self-immolative spacer based on dissymmetrical N,N′-bis-carbamate aniline is introduced to liberate a substrate from a precursor after dual activation. The proof of principle of its exclusive selectivity for substrate liberation has been conducted on a profluorophore.
- Open Access
- 26 April 2021
- Published by Wiley in Angewandte Chemie
- Vol. 133 (27) , 14950-14956
Absolute Quantification of Drug Vector Delivery to the Cytosol
Macromolecular drugs inefficiently cross membranes to reach their cytosolic targets. They require drug delivery vectors to facilitate their translocation across the plasma membrane or escape from endosomes. Optimization of these vectors has however been hindered by the difficulty to accurately measure cytosolic arrival. We have developed an exceptionally sensitive and robust assay for the relative or absolute quantification of this step. The assay is based on benzylguanine and biotin modifications on a drug delivery vector of interest, which allow, respectively, for selective covalent capture in the cytosol with a SNAP‐tag fusion protein and for quantification at picomolar sensitivity. The assay was validated by determining the absolute numbers of cytosolic molecules for two drug delivery vectors: the B‐subunit of Shiga toxin and the cell‐penetrating peptide TAT. We expect this assay to favor delivery vector optimization and the understanding of the enigmatic translocation process.
- 26 April 2021
- Published by Wiley in Angewandte Chemie
- Vol. 133 (27) , 14950-14956
Open AccessAbsolute Quantification of Drug Vector Delivery to the Cytosol
Macromolecular drugs inefficiently cross membranes to reach their cytosolic targets. They require drug delivery vectors to facilitate their translocation across the plasma membrane or escape from endosomes. Optimization of these vectors has however been hindered by the difficulty to accurately measure cytosolic arrival. We have developed an exceptionally sensitive and robust assay for the relative or absolute quantification of this step. The assay is based on benzylguanine and biotin modifications on a drug delivery vector of interest, which allow, respectively, for selective covalent capture in the cytosol with a SNAP‐tag fusion protein and for quantification at picomolar sensitivity. The assay was validated by determining the absolute numbers of cytosolic molecules for two drug delivery vectors: the B‐subunit of Shiga toxin and the cell‐penetrating peptide TAT. We expect this assay to favor delivery vector optimization and the understanding of the enigmatic translocation process.
- Open Access
- 26 April 2021
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 60 (27) , 14824-14830
Absolute Quantification of Drug Vector Delivery to the Cytosol
Macromolecular drugs inefficiently cross membranes to reach their cytosolic targets. They require drug delivery vectors to facilitate their translocation across the plasma membrane or escape from endosomes. Optimization of these vectors has however been hindered by the difficulty to accurately measure cytosolic arrival. We have developed an exceptionally sensitive and robust assay for the relative or absolute quantification of this step. The assay is based on benzylguanine and biotin modifications on a drug delivery vector of interest, which allow, respectively, for selective covalent capture in the cytosol with a SNAP‐tag fusion protein and for quantification at picomolar sensitivity. The assay was validated by determining the absolute numbers of cytosolic molecules for two drug delivery vectors: the B‐subunit of Shiga toxin and the cell‐penetrating peptide TAT. We expect this assay to favor delivery vector optimization and the understanding of the enigmatic translocation process.
- 26 April 2021
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 60 (27) , 14824-14830
Open AccessAbsolute Quantification of Drug Vector Delivery to the Cytosol
Macromolecular drugs inefficiently cross membranes to reach their cytosolic targets. They require drug delivery vectors to facilitate their translocation across the plasma membrane or escape from endosomes. Optimization of these vectors has however been hindered by the difficulty to accurately measure cytosolic arrival. We have developed an exceptionally sensitive and robust assay for the relative or absolute quantification of this step. The assay is based on benzylguanine and biotin modifications on a drug delivery vector of interest, which allow, respectively, for selective covalent capture in the cytosol with a SNAP‐tag fusion protein and for quantification at picomolar sensitivity. The assay was validated by determining the absolute numbers of cytosolic molecules for two drug delivery vectors: the B‐subunit of Shiga toxin and the cell‐penetrating peptide TAT. We expect this assay to favor delivery vector optimization and the understanding of the enigmatic translocation process.
- Open Access
- 1 February 2021
- Published by Elsevier in Data in Brief
- Vol. 34, 106704
Datasets and analyses of molecular dynamics simulations of covalent binary and ternary complexes of MHC class I-related molecule/T-cell receptor (MR1/TCR) agonists to understand complex formation and conditions of fluorescent labelling
- 1 February 2021
- Published by Elsevier in Data in Brief
- Vol. 34, 106704
Open AccessDatasets and analyses of molecular dynamics simulations of covalent binary and ternary complexes of MHC class I-related molecule/T-cell receptor (MR1/TCR) agonists to understand complex formation and conditions of fluorescent labelling
- 25 October 2019
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 366 (6464) , 494-499
Microbial metabolites control the thymic development of mucosal-associated invariant T cells
Commensals rule the MAITrix: Mucosal-associated invariant T (MAIT) cells play an important role in mucosal homeostasis. MAIT cells recognize microbial small molecules presented by the major histocompatibility complex class Ib molecule MR1. MAIT cells are absent in germ-free mice, and the mechanisms by which microbiota control MAIT cell development are unknown (see the Perspective by Oh and Unutmaz). Legoux et al. show that, in mice, development of MAIT cells within the thymus is governed by the bacterial product 5-(2-oxopropylideneamino)-6- d -ribitylaminouracil, which rapidly traffics from the mucosa to the thymus, where it is captured by MR1 and presented to developing MAIT cells. Constantinides et al. report that MAIT cell induction only occurs during a limited, early-life window and requires exposure to defined microbes that produce riboflavin derivatives. Continual interactions between MAIT cells and commensals in the skin modulates tissue repair functions. Together, these papers highlight how the microbiota can direct immune cell development and subsequent function at mucosal sites by secreting compounds that act like self-antigens. Science , this issue p. 494 , p. eaax6624 ; see also p. 419
- 25 October 2019
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 366 (6464) , 494-499
Microbial metabolites control the thymic development of mucosal-associated invariant T cells
Commensals rule the MAITrix: Mucosal-associated invariant T (MAIT) cells play an important role in mucosal homeostasis. MAIT cells recognize microbial small molecules presented by the major histocompatibility complex class Ib molecule MR1. MAIT cells are absent in germ-free mice, and the mechanisms by which microbiota control MAIT cell development are unknown (see the Perspective by Oh and Unutmaz). Legoux et al. show that, in mice, development of MAIT cells within the thymus is governed by the bacterial product 5-(2-oxopropylideneamino)-6- d -ribitylaminouracil, which rapidly traffics from the mucosa to the thymus, where it is captured by MR1 and presented to developing MAIT cells. Constantinides et al. report that MAIT cell induction only occurs during a limited, early-life window and requires exposure to defined microbes that produce riboflavin derivatives. Continual interactions between MAIT cells and commensals in the skin modulates tissue repair functions. Together, these papers highlight how the microbiota can direct immune cell development and subsequent function at mucosal sites by secreting compounds that act like self-antigens. Science , this issue p. 494 , p. eaax6624 ; see also p. 419
- 24 May 2018
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 54 (49) , 6396-6399
A chemically encoded timer for dual molecular delivery at tailored ranges and concentrations
Spatiotemporally controlled dual delivery: a small molecular timer was designed to release two chemicals at programmed intervals, which could be tuned in a wide range.
- 24 May 2018
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 54 (49) , 6396-6399
A chemically encoded timer for dual molecular delivery at tailored ranges and concentrations
Spatiotemporally controlled dual delivery: a small molecular timer was designed to release two chemicals at programmed intervals, which could be tuned in a wide range.
- 23 March 2017
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 15 (16) , 3435-3443
Syntheses and kinetic studies of cyclisation-based self-immolative spacers
Photochemical activation has allowed the precise determination of the disassembly times of cyclisation-based self-immolative spacers. Results confirmed large differences with previously studied elimination-based self-immolative spacers.
- 23 March 2017
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 15 (16) , 3435-3443
Syntheses and kinetic studies of cyclisation-based self-immolative spacers
Photochemical activation has allowed the precise determination of the disassembly times of cyclisation-based self-immolative spacers. Results confirmed large differences with previously studied elimination-based self-immolative spacers.
- 22 April 2016
- Published by Taylor & Francis in OncoImmunology
- Vol. 5 (7) , e1171434
Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen
Antibody-drug conjugates (ADC), combining the specificity of tumor recognition by monoclonal antibodies (mAb) and the powerful cytotoxicity of anticancer drugs, are currently under growing interest and development. Here, we studied the potential of Chi-Tn, a mAb directed to a glyco-peptidic tumor-associated antigen, to be used as an ADC for cancer treatment. First, we demonstrated that Chi-Tn specifically targeted tumor cells in vivo. Also, using flow cytometry and deconvolution microscopy, we showed that the Chi-Tn mAb is rapidly internalized – condition necessary to ensure the delivery of conjugated cytotoxic drugs in an active form, and targeted to early and recycling endosomes. When conjugated to saporin (SAP) or to auristatin F, the Chi-Tn ADC exhibited effective cytotoxicity to Tn-positive tumor cells in vitro, which correlated with the level of tumoral Tn expression. Furthermore, the Chi-Tn mAb conjugated to auristatin F also exhibited efficient antitumor activity in vivo, validating for the first time the use of an anti-Tn antibody as an effective ADC.
- 22 April 2016
- Published by Taylor & Francis in OncoImmunology
- Vol. 5 (7) , e1171434
Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen
Antibody-drug conjugates (ADC), combining the specificity of tumor recognition by monoclonal antibodies (mAb) and the powerful cytotoxicity of anticancer drugs, are currently under growing interest and development. Here, we studied the potential of Chi-Tn, a mAb directed to a glyco-peptidic tumor-associated antigen, to be used as an ADC for cancer treatment. First, we demonstrated that Chi-Tn specifically targeted tumor cells in vivo. Also, using flow cytometry and deconvolution microscopy, we showed that the Chi-Tn mAb is rapidly internalized – condition necessary to ensure the delivery of conjugated cytotoxic drugs in an active form, and targeted to early and recycling endosomes. When conjugated to saporin (SAP) or to auristatin F, the Chi-Tn ADC exhibited effective cytotoxicity to Tn-positive tumor cells in vitro, which correlated with the level of tumoral Tn expression. Furthermore, the Chi-Tn mAb conjugated to auristatin F also exhibited efficient antitumor activity in vivo, validating for the first time the use of an anti-Tn antibody as an effective ADC.